+

WO2006117165A3 - Moyens et procedes de traitement de lesions de la tete et d'accident cerebrovasculaire - Google Patents

Moyens et procedes de traitement de lesions de la tete et d'accident cerebrovasculaire Download PDF

Info

Publication number
WO2006117165A3
WO2006117165A3 PCT/EP2006/004022 EP2006004022W WO2006117165A3 WO 2006117165 A3 WO2006117165 A3 WO 2006117165A3 EP 2006004022 W EP2006004022 W EP 2006004022W WO 2006117165 A3 WO2006117165 A3 WO 2006117165A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
stroke
methods
head injuries
saha
Prior art date
Application number
PCT/EP2006/004022
Other languages
English (en)
Other versions
WO2006117165A2 (fr
Inventor
Ingmar Bluemcke
Eric Hahnen
Florian Siebzehnruebl
Rolf Buslei
Ilker Yasin Eyuepoglu
Original Assignee
Univ Friedrich Alexander Er
Ingmar Bluemcke
Eric Hahnen
Florian Siebzehnruebl
Rolf Buslei
Ilker Yasin Eyuepoglu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Friedrich Alexander Er, Ingmar Bluemcke, Eric Hahnen, Florian Siebzehnruebl, Rolf Buslei, Ilker Yasin Eyuepoglu filed Critical Univ Friedrich Alexander Er
Publication of WO2006117165A2 publication Critical patent/WO2006117165A2/fr
Publication of WO2006117165A3 publication Critical patent/WO2006117165A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation d'inhibiteurs de HDAC pour la préparation d'une composition pharmaceutique permettant d'améliorer, de traiter ou de prévenir des malignités se rapportant à des événements ischémiques ou des lésions cérébrales. L'inhibiteur de HDAC est choisi dans le groupe constitué de SAHA, M344, MS-275, CBHA et SBHA, SAHA étant l'inhibiteur de HDAC préféré.
PCT/EP2006/004022 2005-05-02 2006-04-28 Moyens et procedes de traitement de lesions de la tete et d'accident cerebrovasculaire WO2006117165A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05009614 2005-05-02
EPEP05009614 2005-05-02

Publications (2)

Publication Number Publication Date
WO2006117165A2 WO2006117165A2 (fr) 2006-11-09
WO2006117165A3 true WO2006117165A3 (fr) 2007-04-26

Family

ID=36954780

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/004022 WO2006117165A2 (fr) 2005-05-02 2006-04-28 Moyens et procedes de traitement de lesions de la tete et d'accident cerebrovasculaire

Country Status (1)

Country Link
WO (1) WO2006117165A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007130419A2 (fr) * 2006-05-04 2007-11-15 Merck & Co., Inc. Inhibiteurs de l'histone desacétylase pour le traitement de la neurodégénération
WO2008126932A2 (fr) * 2007-04-09 2008-10-23 Riken Régulation épigénétique de la plasticité du cerveau
US9435813B2 (en) 2010-05-11 2016-09-06 The General Hospital Corporation Biomarkers of hemorrhagic shock
AU2012226586B2 (en) * 2011-03-09 2017-04-13 Cereno Scientific Ab Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors
MX355015B (es) * 2011-09-15 2018-04-02 Univ Taipei Medical Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal.
WO2014137741A1 (fr) * 2013-03-05 2014-09-12 Lixte Biotechnology, Inc. Inhibiteurs de hdac pour le traitement d'une lésion cérébrale traumatique
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
AU2017246697B2 (en) 2016-04-08 2022-06-02 Cereno Scientific Ab Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032921A2 (fr) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Traitement des maladies neurodegeneratives et du cancer du cerveau

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032921A2 (fr) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Traitement des maladies neurodegeneratives et du cancer du cerveau

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BLANCHARD F ET AL: "Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 10, no. 3, 1 February 2005 (2005-02-01), pages 197 - 204, XP004748155, ISSN: 1359-6446 *
CHUANG D-M: "Lithium protection from glutamate excitotoxicity: therapeutic implications", CLINICAL NEUROSCIENCE RESEARCH, ELSEVIER, LONDON, GB, vol. 4, no. 3-4, December 2004 (2004-12-01), pages 243 - 252, XP004732774, ISSN: 1566-2772 *
EYAL S ET AL: "The activity of antiepileptic drugs as histone deacetylase inhibitors", EPILEPSIA 2004 UNITED STATES, vol. 45, no. 7, 2004, pages 737 - 744, XP009048454, ISSN: 0013-9580 *
FARACO G ET AL: "Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain", MOLECULAR PHARMACOLOGY 2006 UNITED STATES, vol. 70, no. 6, 2006, pages 1876 - 1884, XP009077326, ISSN: 0026-895X 1521-0111 *
GLASER K B ET AL: "Differential protein acetylation induced by novel histone deacetylase inhibitors.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 17 DEC 2004, vol. 325, no. 3, 17 December 2004 (2004-12-17), pages 683 - 690, XP004635478, ISSN: 0006-291X *
JEONG M R ET AL: "Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 542, no. 1-3, 8 May 2003 (2003-05-08), pages 74 - 78, XP004422726, ISSN: 0014-5793 *
SUURONEN T ET AL: "Regulation of microglial inflammatory response by histone deacetylase inhibitors", JOURNAL OF NEUROCHEMISTRY 2003 UNITED KINGDOM, vol. 87, no. 2, 2003, pages 407 - 416, XP002415488, ISSN: 0022-3042 *

Also Published As

Publication number Publication date
WO2006117165A2 (fr) 2006-11-09

Similar Documents

Publication Publication Date Title
WO2006117165A3 (fr) Moyens et procedes de traitement de lesions de la tete et d'accident cerebrovasculaire
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2007127158A3 (fr) Modification d'absorption percutanée de matériaux topiquement actifs
WO2008148074A3 (fr) Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
WO2010032875A3 (fr) Composés de carboxamide hétérocycliques
ZA200806778B (en) N-Hydroxyacrylamide compounds
WO2006096434A3 (fr) Compositions pharmaceutiques permettant de traiter et/ou de prevenir les troubles de l'anxiete
WO2011091213A3 (fr) Composés amide inverse en tant qu'inhibiteurs de protéine désacétylase et procédés d'utilisation associés
CL2007001882A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
WO2007077186A8 (fr) Inhibiteurs de pdf
EP2607348A3 (fr) Agent inhibiteur de l'inhibiteur de l'activateur du plasminogène 1
WO2007087431A3 (fr) Pulvérisation sublinguale de fentanyle
WO2007056244A3 (fr) Procedes d'utilisation de saha et d'erlotinibe aux fins de traitement du cancer
CL2007001881A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
WO2008073138A3 (fr) Composés et compositions de téréphtalamate, et leur utilisation en tant qu'inhibiteurs de l'intégrase du vih
DK1954251T3 (da) Sammensætning med langvarig frigivelse, som har jernsalt som aktiv bestanddel, fremgangsmåde til fremstilling deraf og anvendelse deraf
CL2007000918A1 (es) Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
WO2007044325A3 (fr) Inhibiteurs de l'interaction du domaine apoe4 et methodes d'utilisation
WO2008104852A3 (fr) Compositions pharmaceutiques comprenant un adsorbate de fénofibrate
WO2011011420A3 (fr) Inhibiteurs 3, 4-méthylènedioxyphényle d'aminotransférase gaba et/ou de transporteur de recaptage de gaba
WO2008055022A3 (fr) Procédés de traitement de la dépression
WO2007062862A3 (fr) Utilisation d'inhibiteurs de la calmoduline pour traiter des troubles neurodegeneratifs
BRPI0516128A (pt) uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
WO2009148600A3 (fr) Composés à base de lysine deutérée
WO2007095611A3 (fr) Utilisation des derives de benzo-heteroaryl sulfamide dans le traitement de la migraine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06724646

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载